30 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Shanghai Pharmaceuticals has maintained a steady growth in first quarterly result of 2013 touching operating revenues of $3.17 billion (RMB19.59 billion), which is a year-on-year increase of 17.6 percent.
Net profit attributable to shareholders of the company was valued at $101.4 million (RMB 626 million), a year-on-year increase of 8.5 percent.
The company is also making changes to its board of directors. Zuo Min, Zhou Jie, Jiang Ming, Hu Fengxiang, Lou Dingbo, Wan Kam To, Chen Naiwei, Li Zhenfu and Tse Cho Che, were nominated as candidates for the fifth session of the board; Zhang Zhenbei and Xin Keng were nominated as candidates for the fifth session of the board of supervisors, both with a term of three years.
The re-election results of the board of directors this year saw the retention of core members of the previous board in order to ensure a smooth transition and to promote a continuation of the company's long-term strategies.